KAIROS PHARMA, LTD. (KAPA) Provides Business Update
KAIROS PHARMA, LTD. (KAPA) issued a business update covering recent developments.
targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. For more information, visit kairospharma.com. Kairos Pharma Forward Looking Statements This press release may contain forward-looking statements, including information about management’s view of Kairos Pharma’s future expectations, plans and prospects, within the meaning of the federal securities laws, including the safe harbor provisions under The Private Securities Litigation Reform Act of 1995
🔍 Detailed Event Analysis:
AI Summary: Kairos Pharma, Ltd. will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7. The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET.
Key Elements Identified:
Organizations: the Effective Time, DTC, the “Reverse Stock Split
📋 KAIROS PHARMA, LTD. (KAPA) - Other Event
Filing Date: 2026-08-21
Accepted: 2026-08-21 16:30:28
Event Type: Other Event
Event Details:
🔍 Detailed Event Analysis:
AI Summary: Kairos Pharma, Ltd. will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7. The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET.
Key Elements Identified:
💼 Business Developments:
No business developments data available.
Structured Data: